The success of CAR-T treatments for blood cancers has encouraged oncology developers to try to translate the technology to solid tumors. But it’s a challenging task, given the lack of target antigens that are specific to solid tumors.
The quest to translate the CAR-T technology to solid tumors has spawned a number of innovative solutions. They include synthesizing CARs that can be programmed to recognize several tumor antigens simultaneously; attaching cancer-killing viruses to CAR-Ts; and engineering personalized CAR-T cells that target solid tumors based on specific mutations in patients’ cancers.
This Fierce webinar will include input from biopharma researchers who are working on new CAR-T technologies aimed at solid tumors. They will discuss the challenges involved in designing and developing the next generation of CAR-Ts.